Jacobs & Co. CA lowered its position in Pfizer, Inc. (NYSE:PFE) by 1.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 202,564 shares of the biopharmaceutical company’s stock after selling 2,113 shares during the period. Jacobs & Co. CA’s holdings in Pfizer were worth $6,804,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the business. Northstar Group Inc. raised its position in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares during the period. Stone House Investment Management LLC raised its position in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 66 shares during the period. Naples Global Advisors LLC raised its position in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after acquiring an additional 79 shares during the period. Asset Planning Services Ltd. raised its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the period. Finally, SPC Financial Inc. raised its position in shares of Pfizer by 1.8% in the first quarter. SPC Financial Inc. now owns 7,909 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 138 shares during the period. Institutional investors and hedge funds own 68.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/10/10/jacobs-co-ca-has-6-80-million-holdings-in-pfizer-inc-pfe.html.
In other news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the sale, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by company insiders.
Pfizer, Inc. (NYSE:PFE) traded down 0.0398% during mid-day trading on Tuesday, hitting $36.1256. 8,644,656 shares of the stock traded hands. The firm’s 50-day moving average is $34.82 and its 200-day moving average is $33.69. The company has a market cap of $214.85 billion, a price-to-earnings ratio of 26.4269 and a beta of 1.00. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $36.51.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 earnings per share. Equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is currently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.